CoChat

Replacement treatment with biosynthetic human growth hormone in growth hormone‐deficient hypopituitary adults*

Beshyah, Salem A., Freemantie, Christopher, Shahl, Manjit, Anyaoku, Victor, Merson, Stephen, Lynch, Sean, Skinner, Elizabeth, Sharp, Patrick, Foale, Rodney, Johnston, Desmond G. · 1995 · Clinical Endocrinology
Cited by 131

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Summary: OBJECTIVES The physiological role Of growth hormone in adult life has recently attracted increased Interest. We have studied the clinical effects and the effects on body composition of prolonged replacement with biosynthetic human GH In a large number of hypopituitary adults. DESIGN A randomized double blind placebo controlled trial for 6 months followed by an open trial of GH treatment for 12 months. GH dally dose was 0·04 (0·02‐0·05) IU/kg s.c. PATIENTS Forty GH deficient hypopituitary patients (19 M, 21 F; aged 19–67 years) on conventional replacement therapy were studied. MEASUREMENTS Serum insulin like growth factor I (IGF‐I), skinfold thickness, total body potassium, total body water (TBW), exercise tolerance and muscle strength, and well‐being. RESULTS During the 6‐month double blind phase, two GH treated patients withdrew because of adverse events. Lean body mass (LBM) increased and percentage body fat (%BF) decreased on GH but not on placebo (P) (LBM: (GH: from 48·5 ± 9·6 to 49·6 ± 9·5kg; P: from 50·9 ± 9·2 to 50·1 ± 9·0kg, P < 0·05 GH vs P) and TBW (OH: from 34·7 ± 11·4 to 34·2 ± 10·7; P: from 37·4 ± 7·6 to 38·7 ± 8·1, P < 0·05 GH vs P). TBW Increased on GH (P < 0·01) but not on P. No change was observed In waist‐to‐hip ratio or in muscle strength. During longer‐term follow‐up combining the double blind and open phase components of the study, 34, 27 and 11 patients received OH for 6,12 and 18 months respectively. Patients dropped out because of adverse events or lack of perceived benefit. Skinfold thicknesses decreased significantly at 6 and 12 months and the waist circumference at 6 months. Waist‐to‐hip ratio decreased significantly on OH at 12 months. LBM increased on GH treatment from 49·6 ± 9·1 to 51·6 ± 9·4kg (P < 0·0006), 51·9 ± 8·9kg (P < 0·07) and 53·1 ± 10·5 kg (P < 0·0001) at 6, 12 and 18 months respectively. Percentage body fat decreased on GH from 37·2 ± 10·7 to 34·7 ± 10·1 (P < 0·005), 35·1 ± 12·8 (NS) and 34·5 ± 86 (P < 0·04) at 6, 12 and 18 months respectively. TBW also increased at 6 and 12 months of GH treatment. Exercise time increased significantly at 6, 12 and 18 months of GH treatment. Muscle strength in selected muscle groups Increased significantly at 6, 12 or 18 months of GH treatment. Randomization resulted in the placebo group having a greater GHQ score (higher morbidity) than the OH group before therapy. Over the controlled phase, GHQ scores improved on placebo but not on OH and CPRS score was unchanged in either group. In the open phase, the GHQ score did not change on GH therapy but CPRS score improved at 6 and 12 months. CONCLUSIONS Growth hormone replacement therapy in adults for 6 months increased lean body mass, total body water and exercise tolerance, and decreased body fat. Growth hormone replacement for longer than 6 months maintains the advantageous effects seen in shorter‐term studies and may have additional effects on body fat distribution, muscle strength and psychological well‐being.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.1995.tb02601.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 131

Metadata

Authors
Beshyah, S. A., Freemantie, C., Shahl, M., Anyaoku, V., Merson, S., Lynch, S., Skinner, E., Sharp, P., Foale, R., & Johnston, D. G.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
1995-01
Volume
42
Issue
1
Pages
73-84
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2022317574
Cited by
131
References
5
FWCI
5.62
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Replacement treatment with biosynthetic human growth hormone in growth hormone‐deficient hypopituitary adults*. https://app.cochat.ai/papers/10.1111/j.1365-2265.1995.tb02601.x
The paper
Beshyah, S. A., Freemantie, C., Shahl, M., Anyaoku, V., Merson, S., Lynch, S., Skinner, E., Sharp, P., Foale, R., & Johnston, D. G. (1995). Replacement treatment with biosynthetic human growth hormone in growth hormone‐deficient hypopituitary adults*. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.1995.tb02601.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.